0001104659-21-070514.txt : 20210521 0001104659-21-070514.hdr.sgml : 20210521 20210521163114 ACCESSION NUMBER: 0001104659-21-070514 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210520 FILED AS OF DATE: 20210521 DATE AS OF CHANGE: 20210521 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SQUINTO STEPHEN P CENTRAL INDEX KEY: 0001231954 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39044 FILM NUMBER: 21949481 MAIL ADDRESS: STREET 1: C/O ALEXION PHARMACEUTICALS INC STREET 2: 352 KNOTTER DRIVE CITY: CHESHIRE STATE: CT ZIP: 06410 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc. CENTRAL INDEX KEY: 0001773427 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-883-9490 MAIL ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 4 1 tm2117215-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-05-20 0 0001773427 SpringWorks Therapeutics, Inc. SWTX 0001231954 SQUINTO STEPHEN P C/O SPRINGWORKS THERAPEUTICS, INC. 100 WASHINGTON BLVD. STAMFORD CT 06902 1 0 1 0 Common Stock 2021-05-20 4 A 0 1106 0 A 126834 D Common Stock 6186307 I See footnote Stock Option (Right to Buy) 75.94 2021-05-20 4 A 0 6998 0 A 2031-05-20 Common Stock 6998 6998 D Represents restricted stock awards. The restricted stock awards shall vest in full on the earlier of (1) May 20, 2022 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date. Shares held by OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OrbiMed VI. OrbiMed Advisors, LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The options shall vest in full on the earlier of (1) May 20, 2022 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date. /s/ Francis I. Perier, Jr as Attorney-in-Fact 2021-05-21